TY - JOUR
T1 - Early detection of transformation to BPDCN in a patient with MDS
AU - Chamoun, Kamal
AU - Loghavi, Sanam
AU - Pemmaraju, Naveen
AU - Konopleva, Marina
AU - Kroll, Michael
AU - Nguyen-Cao, Madeleine
AU - Hornbaker, Marisa
AU - Dinardo, Courtney D.
AU - Kadia, Tapan
AU - Jorgensen, Jeffrey
AU - Andreeff, Michael
AU - Hu, Shimin
AU - Benton, Christopher Brent
N1 - Funding Information:
This work was supported in part by the Cancer Center Support Grant from the NIH/NCI, P30 CA016672, and was supported by the MDS Clinical Research Consortium.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/10/6
Y1 - 2018/10/6
N2 - Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression of CD56. Historically, patients with BPDCN have an unfavorable prognosis and the optimal treatment is not established due to lack of prospective data. Case report: In this report we describe a patient with Felty's syndrome and myelodysplastic syndrome (MDS) in whom a population of aberrant plasmacytoid dendritic cells emerged while on treatment with decitabine. Approximately 4 months later he transformed to leukemic BPDCN with skin and eye manifestations. Cytogenetic analysis showed diploid karyotype and molecular analysis showed mutations in KRAS, NOTCH1, and RUNX1 genes. He was treated with CD123-targeted therapy and had significant response in his marrow, skin, eyes, and functional status after one cycle. Conclusion: The case demonstrates that minimal transformative disease of BPDCN may be detectable in patients with MDS well before fulminant progression. Early detection of emerging leukemic clones may allow for alternative monitoring and treatment considerations.
AB - Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression of CD56. Historically, patients with BPDCN have an unfavorable prognosis and the optimal treatment is not established due to lack of prospective data. Case report: In this report we describe a patient with Felty's syndrome and myelodysplastic syndrome (MDS) in whom a population of aberrant plasmacytoid dendritic cells emerged while on treatment with decitabine. Approximately 4 months later he transformed to leukemic BPDCN with skin and eye manifestations. Cytogenetic analysis showed diploid karyotype and molecular analysis showed mutations in KRAS, NOTCH1, and RUNX1 genes. He was treated with CD123-targeted therapy and had significant response in his marrow, skin, eyes, and functional status after one cycle. Conclusion: The case demonstrates that minimal transformative disease of BPDCN may be detectable in patients with MDS well before fulminant progression. Early detection of emerging leukemic clones may allow for alternative monitoring and treatment considerations.
KW - BPDCN
KW - Early detection
KW - MDS
KW - Myelodysplastic syndromes
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85054840706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054840706&partnerID=8YFLogxK
U2 - 10.1186/s40164-018-0117-6
DO - 10.1186/s40164-018-0117-6
M3 - Article
C2 - 30323983
AN - SCOPUS:85054840706
SN - 2162-3619
VL - 7
JO - Experimental Hematology and Oncology
JF - Experimental Hematology and Oncology
IS - 1
M1 - 26
ER -